Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1

被引：2

作者：

Harbeck, Nadia ^{[1
]}

Huang, Chiun-Sheng ^{[2
]}

Hurvitz, Sara ^{[3
]}

Yeh, Dah-Cherng ^{[4
]}

Shao, Zhimin ^{[5
]}

Im, Seock-Ah ^{[6
]}

Jung, Kyung Hae ^{[7
]}

Shen, Kunwei ^{[8
]}

Ro, Jungsil ^{[9
]}

Jassem, Jacek ^{[10
]}

Zhang, Qingyuan ^{[11
]}

Im, Young-Hyuck ^{[12
]}

Wojtukiewicz, Marek ^{[13
]}

Sun, Qiang ^{[14
]}

Chen, Shin-Cheh ^{[15
]}

Goeldner, Rainer-Georg ^{[16
]}

Lahogue, Annick ^{[17
]}

Uttenreuther-Fischer, Martina ^{[16
]}

Xu, Binghe ^{[18
]}

Piccart-Gebhart, Martine ^{[19
]}

机构：

[1] Univ Munich, Frauenklin, Brustzentrum, D-81377 Munich, Germany

[2] Natl Taiwan Univ Hosp, Taipei, Taiwan

[3] Univ Calif Los Angeles, David Geffen Sch Med, Translat Res Oncol, Los Angeles, CA 90024 USA

[4] Taichung Vet Gen Hosp, Taichung, Taiwan

[5] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[6] Seoul Natl Univ Hosp, Seoul, South Korea

[7] Univ Ulsan, Coll Med, Asan Med Ctr, Ulsan, South Korea

[8] Ruijin Hosp, Comprehens Breast Hlth Ctr, Shanghai, Peoples R China

[9] Natl Canc Ctr, Singapore, Singapore

[10] Med Univ Gdansk, Gdansk, Poland

[11] Harbin Med Univ, Affiliated Hosp 3, Harbin, Peoples R China

[12] Samsung Med Ctr, Seoul, South Korea

[13] Med Univ, Ctr Comprehens Canc, Gdansk, Poland

[14] Beijing Union Med Coll Hosp, Beijing, Peoples R China

[15] Chang Gung Med Fdn, Linkou Branch, Kaohsiung, Taiwan

[16] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[17] SCS Boehringer Ingelheim Comm V, Ingelheim, Germany

[18] Chinese Acad Med Sci, Cancer Inst & Hosp, Beijing, Peoples R China

[19] Inst Jules Bordet, Brussels, Belgium

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

10.1158/1538-7445.SABCS14-P5-19-01

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P5-19-01

引用

页数：2

共 50 条

[1] Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
Harbeck, Nadia
Huang, Chiun-Sheng
Hurvitz, Sara
Yeh, Dah-Cherng
Shao, Zhimin
Im, Seock-Ah
Jung, Kyung Hae
Shen, Kunwei
Ro, Jungsil
Jassem, Jacek
Zhang, Qingyuan
Im, Young-Hyuck
Wojtukiewicz, Marek
Sun, Qiang
Chen, Shin-Cheh
Goeldner, Rainer-Georg
Uttenreuther-Fischer, Martina
Xu, Binghe
Piccart-Gebhart, Martine
[J]. LANCET ONCOLOGY, 2016, 17 (03): : 357 - 366
[2] LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.
Harbeck, Nadia
Im, Seock-Ah
Huang, Chiun-Sheng
Im, Young-Hyuck
Xu, Binghe
Hurvitz, Sara A.
Lee, Keun-Seok
Ahn, Jin-Hee
Mehta, Ajay O.
Arora, Rajender Singh
Sun, Qiang
Qin, Shukui
Jacob, Linu Abraham
Jassem, Jacek
Staroslawka, Elzbieta
Sufliarsky, Jozef
Wojtukiewicz, Marek
Lahogue, Annick
Uttenreuther-Fischer, Martina Maria
Piccart-Gebhart, Martine J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[3] LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment
Xu, B.
Im, S-A
Huang, C-S
Im, Y-H
Ro, J.
Zhang, Q.
Arora, R.
Mehta, A.
Jung, K.
Yeh, D-C
Lee, S.
Jassem, J.
Wojtukiewicz, M.
Chen, S-C
Lahogue, A.
Uttenreuther-Fischer, M.
Hurvitz, S-A
Harbeck, N.
Piccart-Gebhart, M.
[J]. CANCER RESEARCH, 2012, 72
[4] Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer
Bergen, Elisabeth
Berghoff, Anna S.
Rudas, Margaretha
Dubsky, Peter
De Vries, Catharina
Sattlberger, Claudia
Mader, Robert M.
Zagouri, Flora
Sparber, Cornelia
Fitzal, Florian
Gnant, Michael
Rottenfusser, Andrea
Zielinski, Christoph C.
Preusser, Matthias
Steger, Guenther G.
Bartsch, Rupert
[J]. BREAST CARE, 2014, 9 (05) : 344 - 348
[5] Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
Burstein, Harold J.
Keshaviah, Aparna
Baron, Ari D.
Hart, Ronald D.
Lambert-Falls, Rosemary
Marcom, P. Kelly
Gelman, Rebecca
Winer, Eric P.
[J]. CANCER, 2007, 110 (05) : 965 - 972
[6] LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib
Hickish, T.
Mehta, A.
Jain, M.
Huang, C-S
Kovalenko, N.
Udovitsa, D.
Pemberton, K.
Uttenreuther-Fischer, M.
Tseng, L-M
[J]. CANCER RESEARCH, 2012, 72
[7] Safety of pertuzumab plus trastuzumab in a phase II trial of patients with HER2-overexpressing metastatic breast cancer which had progressed during trastuzumab therapy
Fumoleau, P.
Wardley, A.
Miles, D.
Verma, S.
Gelmon, K.
Cameron, D.
Gianni, L.
Conte, P. F.
Ross, G.
McNally, V
Baselga, J.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S19 - S19
[8] Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment
Sim, S. H.
Park, I. H.
Jung, K. H.
Kim, S-B
Ahn, J-H
Lee, K-H
Im, S-A
Im, Y-H
Park, Y. H.
Sohn, J. H.
Kim, Y. J.
Lee, S.
Kim, H-J
Chae, Y. S.
Park, K-H
Nam, B-H
Lee, K. S.
Ro, J.
[J]. CANCER RESEARCH, 2019, 79 (04)
[9] Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer (vol 9, pg 344, 2014)
Bergen, E.
Berghoff, A. S.
Rudas, M.
Dubsky, P.
De Vries, C.
Sattlberger, C.
Mader, R. M.
Zagouri, F.
Sparber, C.
Fitzal, F.
Gnant, M.
Rottenfusser, A.
Zielinski, C. C.
Preusser, M.
Steger, G. G.
Bartsch, R.
[J]. BREAST CARE, 2016, 11 (01) : 20 - 20
[10] LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L)
Hickish, Tamas
Tseng, Ling-Ming
Mehta, Ajay O.
Tsang, Janice
Kovalenko, Nadezhda
Udovitsa, Dmitry
Pelling, Katy
Uttenreuther-Fischer, Martina Maria
Huang, Chiun-Sheng
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →